Biocon is upbeat about its biosimilars. The Indian biopharmaceutical company expects the sales revenue from this segment to treble by FY15.
Contact us via E-Mail
Follow us on LinkedInAll-time Popular Posts
World’s first biosimilar antibody* is approved in Korea 
A biobetter trastuzumab is on the way - A biosimilar manufacturer: Celltrion
Biosimilar Remicade under review in EU 
Boehringer starts with adalimumab biosimilar - Celltrion’s first biosimilar antibody is about to reach the market
Biosimilars in Emerging Markets 
Indian Biosimilars Market
News/Headlines
-
Biocon hopes sales of biosimilars will triple
Biocon is upbeat about its biosimilars. The Indian biopharmaceutical company expects the sales...
-
Amgen, Hospira and Sandoz named among top pharmaceutical companies with greatest biosimilar potential in USA
The IP & Science business of Thomson Reuters, the provider of intelligent information for...
-
Indian biotech lobby against Cipla’s etanercept
A lobby group of biotech drug companies in India has raised concerns about the approval of Cipla’s...
- Zheijang Huahai and Oncobiologics create broad biosimilars partnership
- EMA revised the biosimilars guideline and public consultation is now open
- Hospira highlights its success of biosimilar offering
Events
-
LabEx MAbImprove industrial workshops of antibody biosimilars
The annual “LabEx MAbImprove industrial workshops” are primarily intended to provide scientists involved...
-
4th Annual Biosimilars Conference
American Conference Institute is organizing the 4th Annual Biosimilars Conference in New York,...
-
A Step By Step Approach To Globalize Your Biosimilar Product workshop
Global Engage/PRA International is organizing the “A step by step approach to globalize your...
- Generics and Biosimilars in Central and Eastern Europe
- Biosimilar monoclonal antibodies: In vitro analytical testing and characterization of quality attributes and potency
- Drug Development Boot Camp 2013
Guidelines
-
EMA revised the biosimilars guideline and public consultation is now open
The European Medicines Agency (EMA) has recently published an updated biosimilars guideline for...
-
Fourth FDA Guidance: Formal meetings between the FDA and Biosimilar product sponsors or applicants
The States’ are working on developing regulations for the upcoming biosimilars boom and at...
-
Egyptian Draft Biosimilars Guidelines
Egypt, last month issued the draft guidelines for Biosimilars Registration on Egyptian Drug Authority...
- EMA revised guideline on low molecular weight heparin biosimilars is ready
- EMA publishes draft guideline on biosimilar insulin products
- EMA to accept biosimilar reference medicines sources outside EEA
Policies
-
First in Nation Biosimilars Bill; patients to be notified if doctor’s prescription changed
The Biotechnology Industry Organization (BIO) commends Virginia Governor Bob McDonnell for signing...
-
MedChi applauds Maryland State Senate action with regard to biosimilars
MedChi, The Maryland State Medical Society applauds passage of legislation in the Maryland State...
-
WLF urged FDA freeze on applications for biosimilar licensing based on pre-2010 reference products
The Washington Legal Foundation last month urged the FDA to defer all work on any applications...
- Colorado doctors will be notified when biosimilars are used
- Amgen’s biosimilar move targets blockbuster biologics
- India to issue compulsory license for Herceptin
Research/Analysis
-
Amgen, Hospira and Sandoz named among top pharmaceutical companies with greatest biosimilar potential in USA
The IP & Science business of Thomson Reuters, the provider of intelligent information for...
-
Research and Markets: Competitor Analysis: Her2 antibodies – trastuzumab biosimilars and biobetters/biosuperiors
Research and Markets has announced the addition of the ”Competitor Analysis: Her2 Antibodies...
-
Improving Patient Recruitment in Biosimilar Trials
Industry Standard Research (ISR), a pharmaceutical market research company, has released a report...
- Research and Markets releases a new report: Global Biosimilars Market
- Outcomes of Biosimilar Development and Commercialisation Conference
- Biotech firms are trying to limit biosimilars in the US
Latest Posts on Biosimilar News
-
Featured News/Headlines
Biocon hopes sales of biosimilars will triple
Biocon is upbeat about its biosimilars. The Indian biopharmaceutical company expects the sales revenue from this segment to treble by FY15.
Read more → -
News/Headlines Research/Analysis
Amgen, Hospira and Sandoz named among top pharmaceutical companies with greatest biosimilar potential in USA
The IP & Science business of Thomson Reuters, the provider of intelligent information for businesses and professionals, announced the release of a life sciences report, “An Outlook on U.S. Biosimilar Competition,” providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.
Read more → -
Featured News/Headlines
Indian biotech lobby against Cipla’s etanercept
A lobby group of biotech drug companies in India has raised concerns about the approval of Cipla’s first biosimilar drug Etanercept, used for the treatment of rheumatic disorders.
Read more → -
Featured News/Headlines
Zheijang Huahai and Oncobiologics create broad biosimilars partnership
Oncobiologics, Inc. announced yesterday that Zhejiang Huahai Pharmaceutical Co., Ltd and Oncobiologics have signed an alliance agreement for the development, manufacture and commercialization of biosimilar monoclonal antibody products.
Read more → -
Featured Guidelines News/Headlines
EMA revised the biosimilars guideline and public consultation is now open
The European Medicines Agency (EMA) has recently published an updated biosimilars guideline for consultation that outlines the general principles that industry must take into account when developing a product and making an application to the agency.
Read more → -
Featured News/Headlines
Hospira highlights its success of biosimilar offering
Hospira, Inc. announced an important milestone, commemorating five years of providing biosimilars to the European market and delivery of more than five million doses of high-quality biosimilar medicines at a lower cost to patients in Europe and Australia.
Read more → -
Featured News/Headlines
Amgen welcomes European Commission report on EU biosimilars uptake
Amgen, a biotechnology company developing both innovative biologic and biosimilar medicines, welcomes a new report from the European Commission detailing Europe’s strong regulatory and commercial foundation for biosimilars in the healthcare marketplace.
Read more → -
Events Upcoming Events
LabEx MAbImprove industrial workshops of antibody biosimilars
The annual “LabEx MAbImprove industrial workshops” are primarily intended to provide scientists involved in research on therapeutic antibodies, a comprehensive view about topics of interest for the pharmaceutical industry.
Read more →
